Janux Therapeutics Shares Tick Up, With Focus Staying on Next Trial Update
Janux Therapeutics shares rose 1.2% to $13.76 Thursday, lagging sector ETFs as investors focused on cash and trial timing. The company reported $956.4 million in cash at March 31 and a $24.4 million Q1 net loss. Its lead drug JANX007 remains in Phase 1b for prostate cancer. Janux’s annual meeting is set for June 11.